The objective of the ABCT Master's degree is to provide the fundamental knowledge and skills required to properly understand the various applications and issues related to biomedicines, cell and gene therapies. The aim is to provide students with high-quality multidisciplinary training (biochemistry, molecular biology, bioinformatic, cell biology, immunology…) enabling them to acquire the skills, competency and expertise in the field of biological drugs and cellular therapies. This international course offers a solid training for future professionals in academic, clinical and industrial research.
International programme ABCT
A multidisciplinary Master's degree from basic and applied sciences to clinical practice
During the two years of the ABCT Master's programme, students will develop competencies aimed at:
- Designing a biomedicine and validate its use in clinical practice
- Designing a tissue, cell or gene therapy medicinal product and validate its use in clinical practice
- Understanding and analyse the role of microbiota in therapeutics
- Evaluating and optimise the performance of a biomedicinal product and an ATMP
- Promoting a scientific project and communicate its results
ABCT Master’s programme is organized over two years:
- Master 1 “from bench” focuses on biological drugs, their mechanism of action, production, exploratory methods, and control stages. The objective is to provide the fundamental scientific and technical bases necessary for understanding biology-based therapies.
- Master 2 “to bedside” places biologically derived medicines in the context of their clinical use. The objective for students is to understand the use of these biological drugs in human medicine and the challenges that remain in patient care.
There are two possible routes to the Master 2 ABCT degree. Either after the Master 1 ABCT or after completing the ABCT course of within the SMPS Master 1 degree.
A master's degree with an international focus
The two-year ABCT Master is an international programme (all courses will be taught in English) giving students an international dimension to their future career path.
The unique feature of the ABCT programme is that it offers a dual track with the possibility for selected students of obtaining a double degree (University of Lille & University of Ramon Llull in Barcelona).
Single diploma - University of Lille
For students choosing the single-degree program, the two semesters of Master 1 and the first semester of Master 2 will take place at the University of Lille. Classes will be taught by specialists and experts in biological medicines and clinicians involved in the use of these innovative medicines.
Double diploma - University of Lille & University Ramon Llull, Barcelona
Students entering the ABCT graduate programme have the opportunity to complete a semester of the Master’s Degree in Bioengineering (https://iqs.edu/en/studies/master-bioengineering/) proposed by the Instituto Químico de Sarrià (IQS), an internationally recognised school of engineering from the University Ramon Llull in Barcelona.
A student must complete at least one semester at IQS and completed the other semesters in Lille to obtain the double degree from the University of Lille and from the University Ramon Llull.
To respond to professional needs
Entering professional life is the natural outcome of this programme. However, our graduates will acquire skills useful for pursuing a PhD programme, thereby deepening their knowledge in the field of biomedicine and cell therapy.
Overall, various professions can be targeted with the ABCT Master's degree, such as:
- Research and development executives
- Specialists in quality assurance and related fields
- Researchers or research professors
For healthcare professionals (medical doctors, pharmacists, dentists), this master's programme will give them an overview of the use of biological drugs in medicine and enable them to develop a critical approach to their use in clinical practice. This master's degree may also be an opportunity for them to enter a doctoral programme.
Several sectors of activities can be targeted:
- Biopharmaceutical industries involved in production of therapies derived from biology
- Both national and international regulatory authorities (EMA, WHO, ANSM, HAS, …)
- Research laboratories (academic and industrial)
- Hospitals